scFv biofunctionalized nanoparticles to effective and safe targeting of CEA-expressing colorectal cancer cells

Colorectal cancer (CRC) is one of the deadliest cancers worldwide, with the 5 year survival rate in metastatic cases limited to 12%. The design of targeted and effective therapeutics remains a major unmet clinical need in CRC treatment. Carcinoembryonic antigen (CEA), a glycoprotein overexpressed in most colorectal tumors, may constitute a promising molecule for generating novel CEA-targeted therapeutic strategies for CRC treatment. Here, we developed a smart nanoplatform based on chemical conjugation of an anti-CEA single-chain variable fragment (scFv), MFE-23, with PLGA-PEG polymers to deliver the standard 5-Fluorouracil (5-FU) chemotherapy to CRC cells. We confirmed the specificity of the developed CEA-targeted NPs on the internalization by CEA-expressing CRC cells, with an enhance of threefold in the cell uptake. Additionally, CEA-targeted NPs loaded with 5-FU induced higher cytotoxicity in CEA-expressing cells, after 24 h and 48 h of treatment, reinforcing the specificity of the targeted NPs. Lastly, the safety of CEA-targeted NPs loaded with 5-FU was evaluated in donor-isolated macrophages, with no relevant impact on their metabolic activity nor polarization. Altogether, this proof of concept supports the CEA-mediated internalization of targeted NPs as a promising chemotherapeutic strategy for further investigation in different CEA-associated cancers and respective metastatic sites.Authors: Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author 1 Given name: [Maria Jose] Last name [Silveira]. Author 7 Given name: [Maria Jose] Last name [Oliveira]. Also, kindly confirm the details in the metadata are correctokAffiliations: Please check and confirm that the authors and their respective affiliations have been correctly identified and amend if necessary.ok

Automated summary

A smart nanoplatform based on chemical conjugation of an anti-CEA single-chain variable fragment (scFv) with PLGA-PEG polymers was developed to deliver 5-Fluorouracil (5-FU) chemotherapy to colorectal cancer (CRC) cells. The developed CEA-targeted nanoparticles demonstrated specificity for CEA-expressing CRC cells and induced higher cytotoxicity. Safety evaluation showed no relevant impact on donor-isolated macrophages. This proof of concept supports CEA-targeted nanoparticles as a promising chemotherapeutic strategy.